SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as the community debates the FDAs release of skeptical briefing documents ahead of an upcoming Advisory Committee meeting for deramiocel, with bulls emphasizing the trial's success and potential dual-label approval while bears highlight regulatory concerns and insider selling. Investors remain locked in a high-stakes discussion over the likelihood of an approval, closely watching the upcoming panel vote as a major binary catalyst.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum is trending following a series of favorable developments, including a strategic grant from the National Science Foundation, a voluntary listing transition to the Nasdaq, and significant enterprise expansion through a partnership with AT&T. While some community members are capitalizing on recent volatility and technical setups, others are focused on the long-term potential of the quantum sector as a national security priority despite ongoing macro-driven price fluctuations.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is trending as investor sentiment shifts following the appointment of a new CEO, Mike Severino, alongside news that the FDA has accepted sNDA filings for two of its Duchenne Muscular Dystrophy therapies. While the community remains deeply divided over the stock's long-term direction, discussions are currently dominated by heavy short interest, debate over potential M&A activity, and optimism that the new leadership will restore institutional credibility ahead of upcoming earnings.

Omeros Corp. operates as a biopharmaceutical company, which engages in the research, discovery, development, and commercialization of small-molecule and protein therapeutics targeting immunologic diseases. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros Corp is seeing significant volatility as investors debate the impact of potentially incomplete sales data, upcoming clinical trial readouts from competitors, and the highly anticipated European regulatory opinion. Community sentiment is polarized between those viewing the price drop as a short-driven manipulation of a fundamentally undervalued stock and others expressing frustration over communication regarding sales growth and the timeline for milestone payments.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

Rigetti Computing is trending as investors digest news of new executive orders focused on accelerating U.S. leadership in quantum technology and secure data migration. The community is actively debating the stock's potential versus broader macro-driven volatility in high-beta tech sectors, with many market participants focused on interpreting how this government policy shift will impact long-term enterprise traction.

Space Exploration Technologies Corp. (SpaceX) designs, manufactures, and launches advanced rockets and spacecraft, including the fully reusable Starship and Super Heavy rocket system, targeting missions to Earth orbit, the Moon, Mars, and beyond. The company is based in Hawthorne, CA and has subsidiaries in Luxembourg and the United States. The company operates Starlink, a low-Earth orbit satellite constellation that delivers high-speed broadband internet worldwide. SpaceX is dedicated to advancing space technology with the goal of enabling human life on other planets. The company was founded in 2002 by Elon Reeve Musk, Kimbal Musk, Michael Kives. Elon Reeve Musk has been the CEO since 2002.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SPCX is facing intense volatility as investors debate the impact of upcoming share lock-up expirations, with community sentiment sharply divided between those viewing the current price as an oversold buying opportunity and those fearing further downside. Discussion is currently focused on whether recent technical progress in Starship flight tests and long-term AI data center potential will be enough to counteract the significant selling pressure expected from institutional and insider share liquidations.

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Replimune Group Inc

Replimune Group is trending due to the company's planned resubmission of its BLA for its melanoma treatment, RP1, following productive discussions with the FDA. Investors are actively debating the potential for an accelerated regulatory path against concerns over the stock's significant cash requirements and the risk of a third clinical regulatory letter.

Forte Biosciences, Inc. is a biopharmaceutical company, which engages in the provision of dermatology products and services. Its lead product includes FB-401, which is a live biotherapeutic for the treatment of inflammatory skin disease, including pediatric and adult patients with atopic dermatitis. The company was founded by Paul A. Wagner on May 3, 2017 and is headquartered in Dallas, TX.

Forte Biosciences Inc

Forte Biosciences is trending following a massive premarket rally driven by the announcement that Argenx will acquire the company in an all-cash transaction at a significant premium. Community discussion is heavily focused on the deal valuation, the integration of FB102 into the acquirer's immunology pipeline, and the stock price currently pinning near the acquisition offer.

Legend Biotech Corp. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, manufacturing, and commercialization of novel therapies for oncology and other indications. The firm develops advanced cell therapies across a diverse array of technology platforms, including autologous and allogeneic chimeric antigen receptor T-cell, gamma-delta T cell and natural killer cell-based immunotherapy. It operates through the following geographical segments: United States of America, China, and Other. The company was founded in 2014 and is headquartered in Somerset, NJ.

Legend Biotech Corp - ADR

Legend Biotech

Legend Biotech is facing significant downward price pressure following a disappointing revenue performance for its flagship CAR-T therapy, Carvykti, which missed consensus estimates and signaled slowing sequential growth. Community sentiment remains deeply divided, with many investors debating whether the stock is a severely undervalued buyout candidate for Johnson & Johnson or a cautionary tale of management failure and rising competition from bispecific combinations.

ProShares Trust II - ProShares Ultra Bloomberg Crude Oil 2x Shares

ProShares Ultra Bloomberg Crude Oil

ProShares Ultra Bloomberg Crude Oil is experiencing significant volatility driven by shifting geopolitical tensions and ongoing diplomatic efforts to address stability in the Middle East. The community is actively debating the potential impacts of a possible ceasefire versus the structural realities of oil supply, with many traders closely monitoring how these headlines influence the leveraged performance of the fund.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


vic88ainfo

Vic88